221 related articles for article (PubMed ID: 36821432)
1. The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
Charbonneau M; Harper K; Brochu-Gaudreau K; Perreault A; Roy LO; Lucien F; Tian S; Fortin D; Dubois CM
Neuro Oncol; 2023 Sep; 25(9):1605-1616. PubMed ID: 36821432
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
Golebiewska A; Hau AC; Oudin A; Stieber D; Yabo YA; Baus V; Barthelemy V; Klein E; Bougnaud S; Keunen O; Wantz M; Michelucci A; Neirinckx V; Muller A; Kaoma T; Nazarov PV; Azuaje F; De Falco A; Flies B; Richart L; Poovathingal S; Arns T; Grzyb K; Mock A; Herold-Mende C; Steino A; Brown D; May P; Miletic H; Malta TM; Noushmehr H; Kwon YJ; Jahn W; Klink B; Tanner G; Stead LF; Mittelbronn M; Skupin A; Hertel F; Bjerkvig R; Niclou SP
Acta Neuropathol; 2020 Dec; 140(6):919-949. PubMed ID: 33009951
[TBL] [Abstract][Full Text] [Related]
3. The Chicken Embryo Chorioallantoic Membrane (CAM): A Versatile Tool for the Study of Patient-Derived Xenografts.
Villanueva H; Sikora AG
Methods Mol Biol; 2022; 2471():209-220. PubMed ID: 35175599
[TBL] [Abstract][Full Text] [Related]
4. A Simple Three-dimensional Hydrogel Platform Enables
Hribar KC; Wheeler CJ; Bazarov A; Varshneya K; Yamada R; Buckley P; Patil CG
Mol Cancer Ther; 2019 Mar; 18(3):718-725. PubMed ID: 30755456
[TBL] [Abstract][Full Text] [Related]
5. The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research.
DeBord LC; Pathak RR; Villaneuva M; Liu HC; Harrington DA; Yu W; Lewis MT; Sikora AG
Am J Cancer Res; 2018; 8(8):1642-1660. PubMed ID: 30210932
[TBL] [Abstract][Full Text] [Related]
6. Characterizing treatment resistance in muscle invasive bladder cancer using the chicken egg chorioallantoic membrane patient-derived xenograft model.
Villanueva H; Wells GA; Miller MT; Villanueva M; Pathak R; Castro P; Ittmann MM; Sikora AG; Lerner SP
Heliyon; 2022 Dec; 8(12):e12570. PubMed ID: 36643309
[TBL] [Abstract][Full Text] [Related]
7. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
[TBL] [Abstract][Full Text] [Related]
8. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response.
Zhang F; Wang W; Long Y; Liu H; Cheng J; Guo L; Li R; Meng C; Yu S; Zhao Q; Lu S; Wang L; Wang H; Wen D
Cancer Commun (Lond); 2018 Sep; 38(1):60. PubMed ID: 30257718
[TBL] [Abstract][Full Text] [Related]
9. A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening.
Zhang L; Liu F; Weygant N; Zhang J; Hu P; Qin Z; Yang J; Cheng Q; Fan F; Zeng Y; Tang Y; Li Y; Tang A; He F; Peng J; Liao W; Hu Z; Li M; Liu Z
Cancer Lett; 2021 Mar; 500():87-97. PubMed ID: 33309780
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
11. The chick embryo chorioallantoic membrane patient-derived xenograft (PDX) model.
Ribatti D
Pathol Res Pract; 2023 Mar; 243():154367. PubMed ID: 36774760
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
13. Cancer "Avatars": Patient-Derived Xenograft Growth Correlation with Postoperative Recurrence and Survival in Pancreaticobiliary Cancer.
Lynch IT; Abdelrahman AM; Alva-Ruiz R; Fogliati A; Graham RP; Smoot R; Truty MJ
J Am Coll Surg; 2023 Sep; 237(3):483-500. PubMed ID: 37326316
[TBL] [Abstract][Full Text] [Related]
14. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway.
Bu X; Qu X; Guo K; Meng X; Yang X; Huang Q; Dou W; Feng L; Wei X; Gao J; Sun W; Chao M; Han L; Hu Y; Shen L; Zhang J; Wang L
Int J Biol Sci; 2021; 17(12):3013-3023. PubMed ID: 34421346
[No Abstract] [Full Text] [Related]
15. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
[TBL] [Abstract][Full Text] [Related]
16. Applications of the Chick Chorioallantoic Membrane as an Alternative Model for Cancer Studies.
Chu PY; Koh AP; Antony J; Huang RY
Cells Tissues Organs; 2022; 211(2):222-237. PubMed ID: 33780951
[TBL] [Abstract][Full Text] [Related]
17. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a ccRCC patient-derived chick chorioallantoic membrane model for drug testing.
Charbonneau M; Harper K; Brochu-Gaudreau K; Perreault A; McDonald PP; Ekindi-Ndongo N; Jeldres C; Dubois CM
Front Med (Lausanne); 2022; 9():1003914. PubMed ID: 36275794
[TBL] [Abstract][Full Text] [Related]
19. Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer.
Ali Z; Vildevall M; Rodriguez GV; Tandiono D; Vamvakaris I; Evangelou G; Lolas G; Syrigos KN; Villanueva A; Wick M; Omar S; Erkstam A; Schueler J; Fahlgren A; Jensen LD
J Exp Clin Cancer Res; 2022 Feb; 41(1):58. PubMed ID: 35139880
[TBL] [Abstract][Full Text] [Related]
20. Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.
Wei S; Yin D; Yu S; Lin X; Savani MR; Du K; Ku Y; Wu D; Li S; Liu H; Tian M; Chen Y; Bowie M; Hariharan S; Waitkus M; Keir ST; Sugarman ET; Deek RA; Labrie M; Khasraw M; Lu Y; Mills GB; Herlyn M; Wu K; Liu L; Wei Z; Flaherty KT; Abdullah K; Zhang G; Ashley DM
Clin Cancer Res; 2022 May; 28(10):2180-2195. PubMed ID: 35247901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
